glp-1 agonist prediabetes for Prevention: Using Drugs Like Zepbound for Pre-Diabetes or Metabolic Risk -What Does Research Say? New GLP-1 Guidelines for Type

Primary outcome The primary outcome, major adverse cardiovascular events (MACE), was reported in all 11 included studies, comprising of 91,490 participants with 4386 MACE events in the intervention group and 4884 MACE events in the placebo group

Table: Comparing the Major GLP-1 Receptor Agonist Drugs To summarize the key characteristics of the GLP-1 drugs up to this point (prior to semaglutide), the table below compares their properties: Table 2: Comparison of GLP-1based therapies

The presence of NAFLD increases the incidence of type 2 diabetes and accelerates the development of complications in type 2 diabetes [5]

The ease of use is another huge plusyou can add it to coffee, smoothies, your morning oats, and more

A nomogram model has been developed to predict the risk of GLP-1RAs in clinical use, which is crucial for the safety and individualized administration of GLP-1RAs in T2DM patients [35]